← Leaderboards
Michael J Boeckh
Fred Hutchinson Cancer Research Center
$14,121,293
Attributed
$26,325,012
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,325,012 · 10
By mechanism
UH3$8,723,851 · 1
U01$5,856,656 · 1
T32$3,967,566 · 1
R01$2,453,768 · 1
UG3$2,341,858 · 1
K24$1,501,719 · 1
Top collaborators
- Abhijit Prakash Limaye10 shared
- Gordon D Rubenfeld10 shared
- Renee D Stapleton6 shared
Most similar at Fred Hutchinson Cancer Research Center
Same institution · by research overlap
- Hua Tang$6,873,773
- Ulrike Peters$61,091,539
- Rainer F. Storb$23,835,935
- Robert Neil Eisenman$37,903,199
- Philip Bradley$9,895,964
Others in their field
Top investigators on “Communicable Diseases”
- Jeffrey P Krischer · University Of South Florida$580,775,398
- Judith S. Currier · University Of California Los Angeles$277,419,428
- Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$240,302,862
- Melynda Holmes · Technical Resources Inc$231,847,503
- Lawrence Corey · Fred Hutchinson Cancer Center$228,424,910
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$227,738,417
Research focus
Communicable DiseasesImmunocompromised HostInfectionMorbidity - Disease RateBaseCytomegalovirusTransplantationVirusViral Load ResultLungPneumoniaHematopoieticPathogenAreaAffectProphylactic TreatmentTransplant RecipientsLeadProspectiveTraining ProgramsProgramsClinical TrialsAdultRespiratory Virus
Grant awards (46)
Training Program in Infectious Diseases in the Immunocompromised Host$631,728
T32 · FY2025 · AI · contact PI
1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis$2,170,027
UH3 · FY2024 · HL · contact PI
Training Program in Infectious Diseases in the Immunocompromised Host$436,073
T32 · FY2024 · AI · contact PI
1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis$2,120,121
UH3 · FY2023 · HL · contact PI
Training Program in Infectious Diseases in the Immunocompromised Host$365,300
T32 · FY2023 · AI · contact PI
1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis$2,216,758
UH3 · FY2022 · HL · contact PI
Training Program in Infectious Diseases in the Immunocompromised Host$505,619
T32 · FY2022 · AI · contact PI
Training Program in Infectious Diseases in the Immunocompromised Host$269,997
T32 · FY2022 · AI · contact PI
1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis$1,503,461
UH3 · FY2021 · HL · contact PI
1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis$713,484
UH3 · FY2021 · HL · contact PI
Training Program in Infectious Diseases in the Immunocompromised Host$323,615
T32 · FY2021 · AI · contact PI
Training Program in Infectious Diseases in the Immunocompromised Host$1
T32 · FY2021 · AI · contact PI
1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis$2,341,858
UG3 · FY2020 · HL · contact PI
Training Program in Infectious Diseases in the Immunocompromised Host$323,928
T32 · FY2020 · AI · contact PI
Training Program in Infectious Diseases in the Immunocompromised Host$319,422
T32 · FY2019 · AI · contact PI
Infections in Hematopoietic Cell Transplant Recipients$116,481
K24 · FY2019 · HL · contact PI
3rd Symposium on Infectious Diseases in the Immunocompromised Host$18,000
R13 · FY2019 · AI · contact PI
Training Program in Infectious Diseases in the Immunocompromised Host$314,400
T32 · FY2018 · AI · contact PI
Infections in Hematopoietic Cell Transplant Recipients$116,481
K24 · FY2018 · HL · contact PI
Training Program in Infectious Diseases in the Immunocompromised Host$315,972
T32 · FY2017 · AI · contact PI
Infections in Hematopoietic Cell Transplant Recipients$116,481
K24 · FY2017 · HL · contact PI
Training Program in Infectious Diseases in the Immunocompromised Host$2,592
T32 · FY2017 · AI · contact PI
Training Program in Infectious Diseases in the Immunocompromised Host$158,919
T32 · FY2016 · AI · contact PI
Infections in Hematopoietic Cell Transplant Recipients$116,481
K24 · FY2016 · HL · contact PI
Infections in Hematopoietic Cell Transplant Recipients$116,481
K24 · FY2015 · HL · contact PI
A Randomzied Phase II Trial of CMV Prevention in Acute Lung Injury$370,684
U01 · FY2014 · HL · contact PI
Infections in Hematopoietic Cell Transplant Recipients$186,369
K24 · FY2013 · HL · contact PI
A Randomzied Phase II Trial of CMV Prevention in Acute Lung Injury$2,118,888
U01 · FY2012 · HL · contact PI
Infections in Hematopoietic Cell Transplant Recipients$187,807
K24 · FY2012 · HL · contact PI
A Randomzied Phase II Trial of CMV Prevention in Acute Lung Injury$2,126,770
U01 · FY2011 · HL · contact PI
Microbiology and Virology Core$367,379
P01 · FY2011 · CA · contact PI
Infections in Hematopoietic Cell Transplant Recipients$185,313
K24 · FY2011 · HL · contact PI
A Randomzied Phase II Trial of CMV Prevention in Acute Lung Injury$1,240,314
U01 · FY2010 · HL · contact PI
Microbiology and Virology Core$262,461
P01 · FY2010 · CA · contact PI
Infections in Hematopoietic Cell Transplant Recipients$181,681
K24 · FY2010 · HL · contact PI
Microbiology and Virology Core$309,230
P01 · FY2009 · CA · contact PI
Infections in Hematopoietic Cell Transplant Recipients$178,144
K24 · FY2009 · HL · contact PI
Respiratory Viruses and Airflow Obstruction after HCT$599,041
R01 · FY2008 · HL · contact PI
Microbiology and Virology Core$285,336
P01 · FY2008 · CA · contact PI
Respiratory Viruses and Airflow Obstruction after HCT$615,972
R01 · FY2007 · HL · contact PI
Microbiology and Virology Core$237,188
P01 · FY2007 · CA · contact PI
Respiratory Viruses and Airflow Obstruction after HCT$608,596
R01 · FY2006 · HL · contact PI
Respiratory Viruses and Airflow Obstruction after HCT$630,159
R01 · FY2005 · HL
CORE--MICROBIOLOGY AND VIROLOGY$0
P01 · FY2002 · CA
CMV AND HIV SHEDDING$0
P01 · FY2002 · HD
CMV AND HIV SHEDDING$0
P01 · FY2002 · HD